Navigation Links
American Oriental Bioengineering Reports Second Quarter 2009 Financial Results
Date:8/7/2009

21,146,928 23,690,440 Goodwill 28,543,226 28,543,226 Long-term investment and advance 55,452,267 54,963,064 Unamortized financing cost 3,751,838 4,215,983 Total Long-Term Assets 387,263,948 391,602,867 TOTAL ASSETS $540,796,581 $524,054,837 LIABILITIES AND EQUITY JUNE 30, DECEMBER 31, 2009 2008 (UNAUDITED) CURRENT LIABILITIES Accounts payable $12,548,451 $12,287,887 Notes payables 3,011,486 3,262,877 Other payables and accrued expenses 14,251,673 19,766,652 Taxes payable 625,261 420,671 Short-term bank loans 6,720,430 7,140,148 Current portion of long-term bank loans 59,396 58,659 Other liabilities 2,511,295 2,253,440 Deferred tax liability 1,121,738 846,026 Total Current Liabilities 40,849,730 46,036,360 LONG-TERM LIABILITIES Long-term bank loans, net of current portion 774,641 804,521 Long-term notes payable -- 269,908 Deferred tax liabilities 15,963,766 16,083,768 Convertible notes 115,000,000 115,000,000 Total Long-Term Liabilities 131,738,407 132,158,197 TOTAL LIABILITIES 172,588,137 178,194,557 COMMITMENTS EQUITY
'/>"/>
SOURCE American Oriental Bioengineering, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
4. American Oriental Bioengineering Announces Participation in September Investor Conferences
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Tips from the Journals of the American Society for Microbiology
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
10. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
11. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... PuraMed BioScience ® , Inc., (OTCBB: ... (OTC) medicinal and healthcare products, announced that Ludlow ... based on low market capitalization valuation. ... Product to Treat Migraine Headaches , Clinical ... , Currently Available Nationwide at Walgreen,s and ...
(Date:5/23/2013)... Calif. , May 23, 2013  Saddleback Memorial ... recently became the first hospital on the West ... technology. This new surgical option provides women with a ... Marc Winter , M.D., a ... and surgeon and medical director of minimally invasive surgery ...
(Date:5/23/2013)... 23, 2013 Northwest Biotherapeutics (NASDAQ: ... ® personalized immune therapies for solid tumor cancers, ... this year,s American Society Of Clinical Oncology (ASCO) meeting ... leadership role in immune therapy.  (Logo: ... is the pre-eminent conference focused on clinical treatment of ...
(Date:5/23/2013)... May 23, 2013 Pusan National University ... private biotherapeutics and contract research company focused on ... cancer, announced today a publication reporting the induction ... the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; ... published in the May 15 th , 2013 ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... , ROCKAWAY, N.J., Dec. 14 ... Approach , published by the Infusion Nurses ... extravasation.(1) Anthracyclines are a group of chemotherapy medications including ... the treatment of various types of cancer since the early ...
... , WALTHAM, Mass., Dec. ... that it has signed a new, three-year master services ... and services that serve patients in approximately 100 countries. ... for translation of the company,s online content, which includes ...
... WALTHAM, Mass., Dec. 14 Decision Resources, one of the world,s ... that, owing to the launches of several new agents, the atrial ... in 2008 to $6.1 billion in 2018 in the United States, ... new Pharmacor report entitled Atrial Fibrillation finds that a ...
Cached Biology Technology:Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 2Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 3The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2
(Date:5/22/2013)... fuel cell powered buses, including a team from ... degradation processes and bus membrane durability. , The ... stressors in the operating cycle of the bus ... the study, led by SFU graduate student Natalia ... at Burnaby-based Ballard Power Systems and funded by ...
(Date:5/22/2013)... drastically reduces the time and effort needed to ... biotechnology, scientists are reporting. Published in the journal ... the way for more rapid development of designer ... activities. , Keith Shearwin and colleagues explain that ... material DNA into a bacterium,s genome is critical ...
(Date:5/22/2013)... how climate change will affect interactions between species in ... of Animal Ecology . This knowledge, they say, is ... how species are likely to be impacted by rising ... among biologists that climate change is affecting how species ... to have very important consequences for the stability and ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5
... new genetic disease that can lead to severe liver damage. ... liver cells are exposed to the toxic components of the ... cells into connective tissue with a gradual loss of liver ... cirrhosis of unknown origin and open up a new approach ...
... one of the "fathers" of the field of ... seventh annual American Association for Cancer Research (AACR)-Prevent ... Research. The award is given annually to ... of cancer prevention research in basic, translational, clinical, ...
... a simple gene-based blood test that more accurately and ... current tests. The test, a measure of inflammatory gene ... backlog of promising medications now hung up in clinical ... small "proof-of-principal" trial in the online version of ...
Cached Biology News:Toxic bile damages the liver 2Meyskens honored with AACR-Prevent Cancer Foundation award 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 3
Request Info...
Polyclonal Antibody to CLAN...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: